Fermentation is one of the most widely used manufacturing processes in modern medicine, responsible for producing everything from antibiotics and vaccines to cancer drugs and cholesterol-lowering medications. The global precision fermentation market is valued at roughly $4.9 billion in 2025, with pharmaceutical applications growing faster than any other segment. Far from its ancient roots in bread and beer, fermentation now powers bioreactors the size of swimming pools, where carefully engineered microorganisms churn out life-saving molecules that would be impossible or impractical to synthesize any other way.
Antibiotics Still Start With Fungi
Penicillin, the drug that launched the antibiotic era, is still produced by fermentation. Industrial strains descended from Penicillium chrysogenum NRRL 1951 have been refined through decades of selective breeding to yield at least a thousand times more drug than the original mold. In a modern facility, a starter culture is grown in progressively larger vessels until it reaches a production fermenter holding around 80,000 liters. The actual fermentation cycle in that final tank takes about six days, during which the fungus secretes penicillin as a byproduct of its metabolism. The drug is then extracted, purified, and processed into the tablets or injectable forms used in clinics worldwide.
Insulin and the Rise of Recombinant Medicine
Before the 1980s, insulin for diabetics came from pig and cow pancreases. Today, virtually all insulin is made by fermentation using genetically modified bacteria. The process works by inserting the human gene for insulin into E. coli bacteria, which then produce the protein in large fermentation tanks. After fermentation, the insulin accumulates inside the bacterial cells in dense clumps called inclusion bodies. These are isolated, dissolved, and then chemically reshaped and purified through multiple steps until the final product is identical to the insulin your own pancreas would make.
This same approach, using living cells as miniature protein factories, now underpins an entire class of medicines called biologics. It transformed insulin from a scarce, animal-derived product into something that can be manufactured at scale with consistent quality.
Monoclonal Antibodies and Large-Scale Cell Culture
Some of the most important drugs developed in the last two decades are monoclonal antibodies, engineered proteins used to treat cancers, autoimmune diseases, and inflammatory conditions. These molecules are too complex for bacteria to assemble correctly, so they’re produced using mammalian cell fermentation instead.
Chinese hamster ovary (CHO) cells are the dominant host for this work. They’re grown in stainless steel bioreactors that can hold anywhere from 10,000 to 25,000 liters. The cells float in nutrient-rich liquid, multiplying and secreting antibodies into the surrounding broth, which is then harvested and purified. Major biopharmaceutical companies have built entire manufacturing campuses around banks of these massive bioreactors to keep up with demand. Drugs like adalimumab (for rheumatoid arthritis) and trastuzumab (for breast cancer) all depend on this fermentation-based production.
Vaccines Grown in Yeast
The hepatitis B vaccine is a textbook example of fermentation in preventive medicine. Rather than using weakened or killed virus, which carries inherent risks, the vaccine is made by inserting a piece of the hepatitis B virus gene into common baker’s yeast (Saccharomyces cerevisiae). The yeast cells are then fermented in a medium of yeast extract, soy peptone, sugars, amino acids, and mineral salts. During growth, the yeast produces a harmless viral surface protein. After fermentation, the yeast cells are broken open, and the protein is extracted and purified through a series of physical and chemical steps. The result is a completely non-infectious vaccine that trains your immune system to recognize and fight the real virus.
Cholesterol Drugs From Mold
Statins, the most widely prescribed class of cholesterol-lowering drugs, trace their origin to fungal fermentation. Lovastatin, the first commercially available statin, is a natural product of the mold Aspergillus terreus. The fungus produces lovastatin as a secondary metabolite, meaning it’s not essential for the organism’s survival but is generated under specific environmental conditions. Production is triggered in part by oxidative stress within the fungal cells, which activates the genes responsible for assembling the molecule. Industrial fermentation of A. terreus remains a key source of lovastatin and serves as the chemical starting point for several semi-synthetic statins that followed.
Cancer Treatment With Bacterial Enzymes
One of the more elegant uses of fermentation in oncology involves an enzyme called L-asparaginase, a frontline treatment for acute lymphoblastic leukemia (ALL), the most common childhood cancer. The enzyme works by breaking down asparagine, an amino acid, in the bloodstream. Healthy cells can make their own asparagine, but many leukemia cells cannot. Starved of this building block, the cancer cells stop growing and die.
L-asparaginase is produced by fermenting bacteria, primarily E. coli and Erwinia chrysanthemi. The enzyme is then extensively purified before clinical use. Researchers are also exploring production from Bacillus species, and the drug’s therapeutic potential is being investigated for solid tumors beyond leukemia.
Immunosuppressants for Transplant Patients
Cyclosporine A, one of the drugs that made organ transplantation practical, is produced by fermenting the soil fungus Tolypocladium inflatum. The fermentation typically runs for about 10 days at 28°C in a glucose-based medium at a slightly acidic pH. Without this drug and others like it, the immune system would attack a transplanted organ as foreign tissue. Several other fungal species, including Aspergillus terreus and Fusarium solani, can also produce cyclosporine A, giving manufacturers flexibility in sourcing.
Vitamin B12 Production
Nearly all of the world’s vitamin B12 supply comes from bacterial fermentation rather than animal extraction. Two modified bacterial strains do most of the heavy lifting: Propionibacterium freudenreichii and Pseudomonas denitrificans. Modern optimized processes can yield up to 300 milligrams of B12 per liter of fermentation broth, with recent Chinese patents reporting around 281 mg/L from P. denitrificans alone. This fermentation-derived B12 ends up in supplements, fortified foods, and injectable formulations used to treat deficiency-related anemia and nerve damage.
Probiotics as Living Medicines
Fermentation also produces the bacteria themselves as the medicine. Clinical-grade probiotics are manufactured by fermenting specific bacterial strains under controlled conditions and then stabilizing them for storage. Several Lactobacillus strains have moved well beyond the supplement aisle into evidence-based clinical applications.
Lacticaseibacillus rhamnosus GG is one of the most studied, with European medical guidelines endorsing it for preventing hospital-acquired diarrhea and antibiotic-associated diarrhea in both children and adults. It’s particularly effective against rotavirus-caused diarrhea in kids. L. acidophilus NCFM, combined with B. lactis Bi-07, has shown benefit for bloating in functional bowel disorders. L. casei helps prevent Clostridium difficile infections, a dangerous complication of antibiotic use. And L. gasseri BNR17 has shown potential for improving diarrhea-predominant irritable bowel syndrome.
Newer research is exploring postbiotics, the beneficial compounds that bacteria produce during fermentation rather than the live bacteria themselves. Metabolites from L. plantarum, for example, are being studied for their effects on intestinal barrier function and even as potential therapeutic agents for colorectal cancer through their influence on anti-tumor immunity.
Quality Control and Purity Standards
Fermentation-derived medicines must meet strict regulatory standards before reaching patients. The FDA requires manufacturers to set limits on three categories of impurities: organic compounds, inorganic compounds, and residual solvents left over from processing. For most fermentation products like antibiotics, the purification and downstream processing steps are effective enough at removing leftover growth media, residual proteins, and nucleic acids from microbial cells that these contaminants don’t even need separate limits in the final specification.
For complex fermentation products that can’t be fully characterized by their structure or biological activity, acceptable impurity levels are determined case by case. Products that will undergo further chemical modification or purification are held to less stringent intermediate standards, while finished drugs ready for patient use face the tightest controls. All residual solvent limits must conform to established pharmacopeial standards.